Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones

By Yahoo! Finance | Nov 19, 2024 at 02:28 PM EST

Cantor analyst Josh Schimmer and JP Morgan analyst Eric Joseph initiated coverage on biopharma company Septerna (SEPN) with an Overweight rating. Schimmer highlights SEPN's innovative GPCR-targeting platform and lead asset, SEP-786, targeting hypoparathyroidism.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.